Related Experiment Video

Updated: May 18, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

The impact of rs231775 (+49AG) CTLA4 gene polymorphism on transplanted kidney function

Leszek Domański1, Katarzyna Bobrek-Lesiakowska, Karolina Kłoda

  • 1Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland.

Annals of Transplantation
|September 29, 2012
PubMed
Abstract

Insights

The rs231775 (+49AG) CTLA4 gene polymorphism G allele is linked to a higher risk of delayed graft function (DGF) in kidney transplant recipients. This genetic factor may impact early kidney allograft outcomes.

Area of Science:

  • Immunogenetics
  • Transplantation Science
  • Molecular Biology

Background:

  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) plays a crucial role in regulating T-cell activation and immune suppression.
  • Genetic variations in the CTLA4 gene, specifically polymorphisms, can influence CTLA4 expression and immune responses.
  • Understanding the genetic basis of immune regulation is vital for optimizing outcomes in organ transplantation.

Purpose of the Study:

  • To investigate the association between the CTLA4 rs231775 (+49AG) gene polymorphism and kidney allograft function.
  • To determine if this specific CTLA4 polymorphism impacts the risk of delayed graft function (DGF) post-kidney transplantation.

Main Methods:

  • Genotyping of the CTLA4 rs231775 (+49AG) polymorphism was performed using real-time PCR.
  • The study included 269 Caucasian kidney transplant recipients.
  • Statistical analyses, including multivariate analysis, were conducted to assess the association with DGF.

Main Results:

  • A higher frequency of DGF was observed in individuals carrying the G allele of the rs231775 (+49AG) CTLA4 gene polymorphism compared to A allele carriers (OR 1.80, p=0.05).
  • Multivariate analysis identified the G allele of the rs231775 CTLA4 gene polymorphism as an independent risk factor for increased DGF.
  • The GG+AG genotype was associated with a significantly higher risk of DGF post-transplantation.

Conclusions:

  • The rs231775 (+49AG) CTLA4 gene polymorphism may be associated with an increased risk of delayed graft function following kidney transplantation.
  • This finding suggests a potential role for immunogenetic factors in predicting early allograft outcomes.
  • Further research could explore targeted interventions based on genetic profiles to mitigate DGF risk.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...